Log inGet Started

Novartis to acquire Avidity Biosciences for about $12 billion - Reuters

AI Summary1 min read

TL;DR

Novartis is acquiring Avidity Biosciences for approximately $12 billion in cash. This deal strengthens Novartis's late-stage neuroscience pipeline by adding Avidity's expertise in RNA therapeutics.

  1. Novartis to acquire Avidity Biosciences for about $12 billion  Reuters
  2. Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash  CNBC
  3. Swiss drugmaker Novartis to buy Avidity Biosciences for $12 billion  USA Today
  4. Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline  Novartis
  5. Novartis Said to Near at Least $70-Per-Share Deal for Avidity  Bloomberg.com

Visit Website